Mogrify wins Business Weekly award for ‘Disruptive Technology’
Direct cellular conversion technology recognized at prestigious business awards.
Cell Mogrify, a UK company aiming to transform the future development of cell therapies, has won the ‘Disruptive Technology’ category at the Business Weekly Awards, in recognition of its novel bioinformatic platform, which is built upon a decade of world-class multidisciplinary science.
Mogrify’s proprietary direct cellular conversion technology takes a systematic big-data approach (Rackham et al., Nature Genetics, 2016) to identify the factors needed to drive the conversion of one mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
Mogrify’s approach is faster and more accessible than iPSC-based protocols as it doesn’t require a licence to use Yamanaka factors to induce pluripotency, it eliminates the need for a two-step approach involving reprograming and differentiation to allow for one-step transdifferentiation, and it produces mature cells rather than converting stems cells to progenitor cells via methods that mimic natural development, which can be slow and time-consuming. The Company is applying its patented technology to generate IP and accelerate the development and manufacture of regenerative cell therapies across every therapeutic area.Professor Julian Gough, Co-founder and CSO, Mogrify, said: “This award is testament to the dedication of Mogrify’s multidisciplinary team who have invested their time and expertise in bioinformatics, cell reprograming and machine learning to deliver a direct cellular conversion platform, powered by next-generation sequencing and gene-regulatory data. Mogrify’s mission is to transform the future of cell therapy and it is an honor to have our disruptive technology recognized at the Business Weekly Awards.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.